* . JUN T /999 Approval date: FREEDOM OF INFORMATION SUMMARY GENERIC NEW ANIMAL DRUG APPLICATION ANADA 200-245 Nystatin, neomycin sulfate, thlostrepton and triamcinolone acetonide cream Derma-Vet Cream’” “.. .Derma-Vet Cream is indicated in the management of dermatologic disorders in dogs and cats, characterized by inflammation and dry or exudative dermatitis, particularly those caused, complicated or threatened by bacterial or candidal (Candida albicans) infections. Sponsored by: Med-Pharmex, Inc. 2727 Thompson Creek Road Pomona, CA 91767-1861 ,,. Freedom 1. of Information Summary. General Information: ANADA Number: 200-245 Sponsor Name and Address: Med-Pharmex, Inc. 2727 Thompson Creek Rd Pomona, CA 91767-1861 Generic Name: Nystatin, neomycin sulfate, thiostrepton and triamcinolone acetonide cream. Trade Name: Derrna-Vet Cream. Marketing Status: Rx. 2. Indications for Use: Derma-Vet Cream is indicated in the management of dermatologic disorders in dogs and cats, characterized by inflammation and dry or exudative dermatitis, particularly those caused, complicated or threatened by bacterial or candidal (Candida albicans) infections. It is also of value in eczematous dermatitis, contact dermatitis and seborrheic dermatitis; and as an adjunct in the treatment of dermatitis due to parasitic infestation. 3. Dosage Form(s), Route(s) of Administration Contraindications: and Recommended Dosages and Dosage Form: Derrna-Vet Cream is in the form of a cream which is applied onto the infected area. Route(s) of Administration and Recommended Dosages: The route of administration is by external application of the cream. The recommended dosage is that the cream is to be applied as a thin film. For mild inflammations, application may range from once daily to once a week. For severe conditions, the product may be applied as often as 2 to 3 times daily, if necessary. Frequency of treatment may be decreased as improvement occurs. .. Freedom of Information Page 2 Summary Contraindications: Derma-Vet Cream should not be used opthalmically. 4. TARGET ANIMAL SAFETY AND EFFECTIVENESS Under the provisions of the Federal Food, Drug, and Cosmetic Act, as amended by the Generic Animal Drug and Patent Term Restoration Act, (53 FR 50460, December 15, 1988, First GADPTRA Policy Letter) an abbreviated new animal drug application (ANADA) may be submitted for a generic version of an approved new animal drug (pioneer product). New target animal safety data, drug effectiveness data, and human food safety data (other than tissue residue data) are not required for approval of an ANADA. Rather, approval of an ANADA relies on the ANADA sponsor showing that the generic product is bioequivalent to the pioneer. If bioequivalence is demonstrated through a clinical end-point study, then a tissue residue study to establish the withdrawal time for the generic product is also required. For certain dosage forms, the agency will grant a waiver from conducting an in vivo bioequivalence study (Fifth GADPTRA Policy Letter, 55 FR 24645, June 18, 1990; Bioequivalence Guidance, 1996,61 FR 26182, May 24, 1996). Based on the formulation characteristics of the Inc. was granted a waiver from the requirement for the generic product Derma-Vet Cream. The a topical ointment and contains the same active same concentrations as the pioneer product. 5. generic product, Med-Pharmex, of an in vivo bioequivalence study generic product is administered as and inactive ingredients in the Human Safety: This drug is indicated for use only on dogs and cats. It is not to be used for foodproducing animals. Therefore, the issue of residues and human safety does not arise. 6. Agency Conclusions: This ANADA submitted under section 512(b) of the Federal Food, Drug, And Cosmetic Act satisfies the requirements of section 512(n) of the Act and demonstrates that Derma-Vet Cream (neomycin sulfate, nystatin, triamcinolone acetonide, thiostrepton) when used under its proposed conditions of use, is safe and effective for the labeled indications. -. Freedom of Information Page 3 Attachment: Summw Generic and pioneer labeling Generic – Pioneer – . . . .~.’. .. . NYSTATIN-NEOMYCIN SULFATE-THIOSTREPTONTRIAMCINOLONE ACETONIDE CREAM VETERINARY For Topical Use on Dogs and Cats CAUTION: Federal law restricts licensed veterinarian. ANADA #200-245 Approved by FDA this drug to use by or on the order of a ~ Nyatatin-Naomycin Suffata-T?riostreptonTdamcfnobne Acetcnide Cream carsbines nystatin, naomycrn suffate, W@repton, and tdamcinolane acehmide. Each gram contains Nystatin . .. ... ... ... ..... .... . ........ ... ... ... ... ..... .. ... .. .... lC0,000 units Neamycfn Suffale aquivabnt to neomycin base .... .....2.5 mg. Thiostrepton ........ .. ... ...... ... .. ..... ....... ..... .. .... .. ......... 2500 units Trfamclnofene acetonida .. .... ..... ... ... ............. ... ........ . 1.0 mg. h an aquaeus, nonirritating vanishing cream base with cetearyl akohef (and) ceteareth-20, ethyiendiamine hydnxhloride, methyl paraban, prepyl paraban. propylene giycol, sotitof solut!ars, Marsium dmxide, sedium citrate, c%ric acid, white patrofatum, gfyceryt monoaleafate, pefyethyfene gfycol menoafearate, sorbic ac!d and slrnethmne. ~ By virtue of its feur actke ingredkmts, NystatinNecnrycln Suffata-Thiestrepton-Triamcinolorne Aca@nida Cream provides [our basic tharapautii affects: antiinflammatory< antipiurftic, ant fiungal and antibacterial. Triamcinolone Acatonide is a potent synthetic catkmsteroid providing rapid and prolonged sYfWtOmafic refief en Iepical administ ratien. Inflemmatirm. ac%msa,and pnmitus pmmpfly subside, and Iesiens are permitted 10 fwal. Nystatin is the first wall tolerated antifungal agent antibmtic of dep%n&bfa efficacy for the traatment of cutaneous “wfectlwss caused by Camfida afbicans (Monitia). Nystatin is fungktatii in vitro agaksaf a vadafy et yeast and yeast fike fungi incfud~ many fungi pathogank to animals. No apprac!able acttii la axhibiied agafnaf bacteria. Thiostrepten has a hgh order d actii~ against gram pesliie organisms, rncluding many whkfr are resistant to other antibiotics naomyc!m exerts antimictobml actien agafnst a wide range C4gram-positive and gram nagatkre bacMfa. Tegather they provide ccsnprahensive therapy agafnst these organisms responsible for most supa!fiiial bacterial fnfacfierss. ~ Nystatin-Nacmycin Suifate-lliostreptenTriamcbmfena Acetenkfe Cream is indwtad in the management of darmatofegk c%order’a h degs and cats, characterize by inflammation and d~ or exudative demratitk, particufarty those CSUS4 wnrpficated or threatenad by bacterial or candidal (Candida atrkans) krfectiens. It k also G4value in eczematous demsatitis; mntacf dermafiik. and sabenheic dermatitis, and as an adjund fn the Iraatmenf ef damsatffii due to parasftii iniestatbn. ~ Nystatin-Neemycin SuffataTfrioslrepten-Trfamclnolefre Acaterdde Cream afrould “ot k epthalmbalty used ~ Nystatin-Nacmyckr Sutfata-ThieatreptonTriamcinofene lwatenida Cream k incJmtej for “se in @s cats onfy. Not for use in anlmafa tiich are raised fer feed. a~ Absorption of tr?amcinofc+seacetcmide thrcugh tcpical appficatico and by ficking may eccur. Therefore animals should be obsetved c!aefy {w signs of pdydiiia, pofyurfa, and inueased weight gain parliculady when the ~eparatien Is used wer farge areas w for etiendad ma d time. Cfin!cal and mpwfrnantsf data have damgnstiatad that atimsteroids adminislared oralfy cf by in@tien to animals may Indwe the first stage ef parfun?ien K used durhg the tast trimester of pregnancy and may pracipiiate premature parturition followed by dyatocia, fetal death, retained pfacanta and metritk. Additionally, corticoatemtis adminiatemd 10 @s, fab4ts and redants during pregnancy have raaufted in daft pa!ate in offspring. C@costertis admiiistemd to dogs during pragnancy have also resufted in other congenital anemafies including deformed forelegs, ph-efii and anasara. ~ Nystatin-Nearnycin Suffat=TtsiireptonTriamcinefene Acatcflide Cream is not intended for the treatment of deep abscesses or deso seated rnfeclem SLM as krffammatiar of the ~phatic vessels. Parenleral antibiotic therapy Is k-rdiitad in these Infecticms. Nystatii-Nwrnycin Suffate-llrbstraptcm-Triamcinolcme Acatonida Cream has bean eslremefy waft tobwatad. Tha eccurrerwe of systemic reactions k rarefy a preblam with topkal administraticm . ,.. . .“ -.. Sensitiiify 10 naomycin may eccur. If redness, irritation or swallii persists or increases, discontinue use. 00 not use H pus is present since [he drug may anew the rnfaclicm to spresd. Avo!d ingestffn. Oral er pamnteral u% of coflicoaieroids, depending on dose, duratii and specific steroids, may result in inhibd”m of andcgenous steroid pmducli-cn following drug withdrawal. SIDF FFFFCIS. . SAP and SGPT (ALT) enzyme elevatkm, pdydipsia and p+uria hava ecwrrad following parenteral or syatamfc use of synthetic cettiisterolds in dogs. Vomiting and diarrhea (eccasienally blwdy) have bean observed in degs. Cushing’s syndrome in dogs has bean reported in association with prolonged er repaatad steroid therapy. ~ Frequency of adminiatratkm is dependent on the saverity of the ccmdtion. Fer mild inflammation, appficatii may range from 01F33daily to once a Suffat& waafc for severe conditions Nystatin-Nacmydn Thiostrepton-Tdamcfnolona Acetenide Cream maybe appliad as oftem as 2 to 3 times dally, il necessary. Fraquency of traaiment may be decreased as Imprcwamant cccurs. Ciaan affected areas, remwing any encrusted discharge 01 exudate. Appfy Nystatin-Naomycin Suffate-ThiostreptcnTriamcinolcma Acatonide Cream spadngiy in a thin film. klmf sfJwLJEQJ . Nystatin-Neomycin Suffate-Thiostreptom Triamcinolcne Acetonide Cream is auppliad in 7.5 gram and 15 gram tubas. April 1999 Mamdacturad by Mad-Phamrez Inc. Pomona, CA 91767 ,. ‘ ,. ---—-—-— . .. —.. —. . . ..—.—--.—— .. R13w?lb-m+. . f4xr331m3A34-- . . dWlW4 WWkD’J 3384 --------------- 1 .. -. — - -------- “ANO SIKI ON SxKJtmmllww)lnfn -uwes’mwns!%lmm Daw4E01/@Iv :-ml ICml “WmwJJi m m-titi ‘mmiwmu IOato alwzmcd ‘mmmxlu @4a ‘umwJm Wm ‘m 341’JW.q31urqm ‘WWP !MWJil ‘wlPlm IWm ‘=40 WAaoJe ‘WeMkmti Wm@nmU WJqqWpfJj $W.W%W4P ‘OZ-WO=W IPJ8)Im$m Im4m?llm CSw Uml$ Cqqqlm SncelmUcIJ H1 31 Mu “k/L g ~ ~,.. -1--..” . . . . . . ...-% -Iw,l qmm.-..-.....--.....umwm~ m Sz--w%q wummo~W’rA!r& !I m wwt-’-’’’’’”’-”-’”’’”””””-w* :Smlml URfl W?43 ------- vWAdc=J33W MM%’WS ~ aN3dw 4 - ,. ,, .* I t 1 1 1 1 1 : I I 1 1 I : 1 I 1 I I 1 6 g 1 :~N31Nw I EN wn4mww0z#wV?w L9L[ 6 V2 ‘VNOLNOd “2NI ~cuuXdWXVHd-CHW iMPWJKJu Dio BPJoa4w @ Wl%lj%lmwwl my pmpy :llq~ (UIO*12 Oplualtsv Ouo(oulauloll -uOld*iirOlui-9 i0ilnS U154U00N.ullDIIAN wv3kia Ill13Awwlf3a Jo ! ,;, . . . .. . . %. .,. :.:. -,,t..,y ,.,. ,., ,,.,.,..,,:,. . ........... $+~,ijj:j.;!:!~~ ,.,... ;.Ji ,,... ~ ~j”’&,:+ $ ,,1 J@+<t ,, “ ‘ :A\,~:,y~,. (&.:\\jy~::.: .. .,,.: :>;; .,,.,. .,y.. —— ‘ ..,, ,., .; ...... ,,““;;;;;;; .,,. ....... ,. . ..... ,,. , !. ,.,’ ,.. .- ,. ..; - . .—..-.——-... >. 4 eloPuWIV ,, Y, ;$ ,, .z. “.~~ E ,% ,.,.:, ..,. ,.>: :.:, .,, ,, z —...y. .. . . ~zob.br Vsn U! PaY-J!Jd W6 L Aw www OZ1!X NkV ‘s@!aH ‘“3UI ‘L#leaH Joj leU.J!UV fzoiw ——. ‘Alleo!wleq]qdo Aqpama~ejnuew aq ‘uo!leJ]s!u!wJpe @$!dol ~l!M UJalqOJd e AlaJeJs! sUo!]oeaJ o!wa]sAs )0 a3uaJJn330 paleJalo] !laM AlauzaJlxa uaaq seq ueaJ~ 13qoued — .. . ... .. .... . *P--------- .-. -.. - . . . .. — . . . . . . . . . ..-. .__.. a.zob”w azotw- AVAII)S ‘H“q 0PS80fN ‘UW~U!Jd‘“WI‘SUOsq qq!nbs IIII1I ‘Saqnl UJwfis Ipue weJ6 S“L u! pa!lddns s! (UJeaJ~ ap!uola3v aUOIOU!XJJe!J~UO\daJISO!~ .ale)lns u!3AuJoaN-u!)elsAN) LueaJ~ 5oloued L1311ddflSMOH ‘Uq!j u!ql e u! A@!Jeds tuea~~ 6010Ued Alddv ‘alepnxa JO 15Jeq3s!p pa]snJ3ua Aue 6u!AowaJ ‘seaJe pa13a~e ueal~ smmo ]UaUJaAOJdWl se paseaJ3ap aq Aew wau4eaJl )0 AwanbaJ~ ‘hessaoau ~! ‘Al!ep saI.u!l c 01 z se uat~o se pa!ldde aq Aew weaJQ 6oloued SUO!I!PUOOaJahas Jo~ $aaM e awo 01 Al!ep aouo WOJJa6ueJ Aew uo!le~!ldde ‘SUO!WIJUJPIJU!pl!uJ Ioj wo!I!puo3 aq] JO h!JaAas aqj uo ]uapuadaps! uo!leJlstu!wpe /0 hanbaJj NOllVHISINIWtlV aNv 39vsaa AdeJaqi p!oJa]s pa]eadaJ JO pa6uoloJd qt!A4 uo!le!sosse u! pauOdaJ uaaq Seq stop u! aUJOJpUASS,BU!qSn~ ‘s60p u! pa~asqo uaaq aAeq (Apoolq Alleuo!seno] eaq]Je!p pue fIu!I!uJoA s60p u! sp!oJa]soo!uo3 o!laqluAs JO asn o!wa$As JO leJaluaJed 6U!MOIIOJ paJJnXto aAeq e!JnApd pue e!sd!pAlod ‘suo!leAala aukua (LIv) ldgs pue dvs suo!va~u! asaql UI pale3!pu! SI AdeJaLp O!lo!q!lue leJaluaJed ‘slassaA ~!]e~dtil aW )0 uo!]ewuel;u! se yms suo!]oa)u! pajeas -daap JO Sassaosqe daap }0 kIaauleaJJ aql Jo~ papualu! IOU s! (weaJ~ ap!uo]am,i auolou!2we!J~uolda4 so!ql -a]eJ/ns U!3AUJOaN-U!]?lSAN) weaJ~ 6oloued pasn aq IOU ppoqs weaJ~ 5oloued SNO11VOI(INIVIJLN03 Aoeo!/~a alqepuadap JO a!lo!q!we IefiunJllue PaleJalol .llaM ISJ!I aws! U!lelSAN leaq 01 pau!wJad aJe suo}sal pue %p!sqns ApdwoJd snJ!JnJd pueewapa‘uo!jewwel~ul wo!~eJls!u!wpe Ieo!dol uo la!iaJ 3!leUoldwAs Pa6UO(Od pUe p!deJ 6u{p!AOJd P\OJalS031\JOl 3uaWuAS auolouwe!ji ‘leljal~ewe wa]od es! ap!uola~e pue le6un~!]ue ‘3!l!JnJd!v.Je “tiolewwelju!-lwe :s]]aj}a 3!madeJaql o!seq mo] sapmold lweaJ~ ap!uoialtj auoloU!2We!J1-UO] daJISOlq -ale)lfls u12AWOaNwllelsANJ weaJ~ 6oloued ‘swa!paJ“{ UI aA!\3e J170) SII )0 afllJIA Ag SNO113V vo!ielsa)u! 3!]! SeJed O] anp s!l!lewJap JO ]uawleaJ] aql u! wnfpe ue se pue :s!l!lewJap 3!aqJJoqas pue s!]!] ewJap ]oeluoo ‘s!l!lawJap Snolewazoa u! anleh JO osles! II suo!]3ap! (wwe wowo) lep!pue2 JO \e!JaDeq Aq paua\eaJql JO ‘pale3!lduo3 ‘pasne3 asoq] AIJelfl!J!]Jed ‘s!]! ]ewJap aA!lepnxa JO AJp pue uo!lewwelp! Aq paz!Ja]oeJeqo ‘s]eo pue s60p UI sJapJos!p 3!6010]ewJap JO luawa6euaw aq] U! pa~e$!pu! s! (weaJ~ ap!uo]aov auolou!3we!J~uo]daJ] so!ql -a)eJlns u!3AwoaN-u!]elsAN) weaJ~ 6oloued SNOWNONI ‘suo!]ta~u! le!Ja]seq le!3!/Jadns ISOW JOJ alq!suodsaJ sws!ue6Jo asoql lsu!e6e AdeJaql a.h!suaqaJdluo3 ap!AOJd Aaql Jaq@o~ “e!Ja]3eq aA!]e6au-weJ6 pue aA!]!SOd -UJeJ6 JO a6ueJ ap!m e jsu!e6e uo!ve le!qoJ3!uJ!we suaxa u!~hoau :s3!]o!q!we Jaq]o 01 weis!saJ aJe WJ!qM Auew fiu!pnpu! ‘sws!ue6Jo aA!]!SOd-WeJ6 lSU!e6e Al! A!12e /0 JapJO 146!u e Seq UOldaJ]SO/~1 ‘e! Ja13eq ]su!e6e pal!qfqxas! Al!A!13e alqe!3aJdde ON “slaw!ue 01 o!ua60q]ed !bunj Auew 15u!pnpu! @zn} ay!l]seaA pue ]seaA )0 ka!JeA e vsu!e6e OJ//A ~!lels!6un\s! u!lewAN (e!i!uo~) sumw wfw suo!]oaju! snoauemo /0 waw]eaJ] aq] Joj SNOllflV33tld ‘e2Jeseue pue e!la~oooqd MalaJo) patuJo~ap 6u!pnpu! sa!lewoue lej!ua6u02 Jaqlo u! pallnsaJ osle am~ Aweu6aJd 6u!Jnp s60p 0] paJaw!u!wpe sp!oJa]so2!lJo ~ fh!,ds),ou! a]eied ijap u! palpIsaJ aAeq A2ueu6aJd u!Jnp sluapoJ pue sl!qqeJ ‘s80p 01 paJals!u!wpe sp~oJa]soo~poo ‘A~leuo!]!ppv auo31qjawls pue p!oe 3!qJos ‘a]eJealsouow I03A16 aualAtoaAlod ‘a]eJea]souow @a3A16 ‘wm]e/oJlad a]lqM p!3e 31JI13 ‘aleJ]!3 wmpos ‘ap!xo!p wn!uei!i ‘UOITUOSlo\!qJos ‘I03A16 aualAdoJd ‘uaqeJedlAdoJd ‘uaqeJedlAqlauJ ‘aP!JOpl~oJPAq au!we!pauak4qla ‘OZ-q]aJea]a3 (puej loqo3te lAJea]a3 aseq u.teaJ36u!qs!ueA 6u!ie]!JJ!uou ‘snoanbe U? UI q]!M 6W 0“[ ““””””’”’’’’”’’”’’’’’’”’’’’’””””” aplUO]a3e ooo’ofj~ ~~~~~~~~~~~~~~~~~ ~~ ~~~~~~~~ ,sule]um Aqpasnes sle~ uJeaqj ap!uolaqj auolou!3we!J1-uoldaJJso! ALIVNIWHA ‘aw!l }0 spo!Jad papualxa JOJJO seaJe a6Jel Jaho pasns! uo!leJedaJd aq~ uaqm AIJelna!ved ‘u~e6 @!aM paseaJ3u! pue e!JnAlod ‘e!sd!pAlod JO SU6!S Jo~ Alasolo paAJasqo aq plnoqs Slew!ue aJo}aJaqL ‘mm Aew 6u!qo!I Aq pue uo!leo!ldde Ieo!do] q5noJ~ ap!uolaae auolou!wue!Jl JO uo!ldJosqv aUOIOUIXUelJ: s]!un ooq’z “ ““””” ““’”’””””’””’” “ uoldallso[ql aseq unAwoau Ihq’z ““”” ““’””’’’’”’”’”’’”’” “’’”’’””’’”’””” IUatehmba a]e~lns u!]hoa(; si!un o! u\]e]sAu wejb q3e; “apwo]aoe auolou!otue’!l] pue “uo]daj]sol~l ‘a]e~lns u!oAwoau ‘u!le]sAu Sau!qwoo weaJ~ 5oIoc?d NOlldlH3S30 u! “s!l!Jww pue e]uaoeld pau!e]aJ ‘q]eap lela~ ‘e!oolsAp Aq paMoIIo~ uo!l!mued aJniewaJd ale]!d!oa~d Aew pue hueu6ad JO Jalsaw!Jl lsel aq] 6u!Jnp pasn )! uoJJ!JnlJed }0 a6els lsJ!~ aqj ampu! Aew s[ew!ue OJ UO!]3alU! Aq JO AlleJo paJa]S!U!UJpe Sp!OJa]SOLl!]J03 leq] paleJlsuouJap aAeq elep [eJUaW!JadXa pue leo!u!l~ sm4J33als “jeMeJp~]fM L%JP 6u!MOjI0/ uo!]2flpOJd p!OJa]S snouabopua JO uo!l!q!qu! u! llnsaJ Aew ‘p!oJals o!J!3ads pue uo!]eJnp ‘asop uo fiu!puadap ~sp!oJa]soo!Uoo JOasn \eJaluaJed 10 leJO wo!lsa6u! p!oAv “peaJds 01 uo!loa~u! aqi moile AeuJ 6nJp aql aou!s wasa}ds! snd $! asn 10U ou “asn anu!luo3s!p ‘SaSeaJW! JO s]s!sJad 6U!llaMS JO uo!lel!JJ! ‘SSaupaJ JI “Jnmo Aew u!oAwtoau 01 h!h!\!SUaS ql-aJe41n pue s600 uo asn Ieoldol Joj S u!3hLJoaN-u!lewiN lAIVEllK) (@070NVd 1[11 wepeupkwh pasuem[ e JO.sep~o aq] uo JO Aq asn OJ Einlp sw WJplsiu Mel leJaPa+ :NOIHIKI ‘pooj JOj pasplJ aJe lp!l+vl slew!ue u! asn JOJ10N ‘AIUO S\eo pue s60p u! asn JO) pala3!pU!s! weaJ~ 6010Ued 3zob-PP S9NINWM E_- :!$:..(,.;
© Copyright 2024